Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02026349 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Efficacy and Safety Study of Favipiravir for Treatment of Uncomplicated Influenza in Adults - T705US316
A Phase 3 study, sponsored by MDVI.
- Completed
- Registry status
- Phase 3
- Development phase
- 860
- Enrollment target
NCT02026349 is a Phase 3 study that has completed, run by MDVI. The registered enrollment target is 860 participants.
The verdict
NCT02026349, a Phase 3 study, has completed, sponsored by MDVI.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 860 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if favipiravir is effective in reducing the time to resolution of influenza symptoms.
Interventions
- DRUG Placebo
- DRUG favipiravir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 860 participants |
| Start Date | 2014-01 |
| Est. Completion | 2015-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02026349
The ClinicalTrials.gov registry entry for NCT02026349 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 860 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MDVI, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02026349 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02026349 about?
NCT02026349 is a clinical study titled "Phase 3 Efficacy and Safety Study of Favipiravir for Treatment of Uncomplicated Influenza in Adults - T705US316". The purpose of this study is to determine if favipiravir is effective in reducing the time to resolution of influenza symptoms.
What is the current status of trial NCT02026349?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 860 participants. The study started on 2014-01. Estimated completion is 2015-03.
What interventions are being tested in trial NCT02026349?
The interventions under investigation include: Placebo (DRUG), favipiravir (DRUG).
Who is sponsoring clinical trial NCT02026349?
This trial is sponsored by MDVI, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.